Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

115 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors.
Sweeney CJ, Chiorean EG, Verschraegen CF, Lee FC, Jones S, Royce M, Tye L, Liau KF, Bello A, Chao R, Burris HA. Sweeney CJ, et al. Among authors: chiorean eg. J Clin Oncol. 2010 Oct 10;28(29):4513-20. doi: 10.1200/JCO.2009.26.9696. Epub 2010 Sep 13. J Clin Oncol. 2010. PMID: 20837944 Free PMC article. Clinical Trial.
A phase II study of gemcitabine in combination with radiation therapy in patients with localized, unresectable, pancreatic cancer: a Hoosier Oncology Group study.
Cardenes HR, Moore AM, Johnson CS, Yu M, Helft P, Chiorean EG, Vinson J, Howard TJ, Stephens AW, Tai DF, Loehrer PJ Sr. Cardenes HR, et al. Among authors: chiorean eg. Am J Clin Oncol. 2011 Oct;34(5):460-5. doi: 10.1097/COC.0b013e3181e9c103. Am J Clin Oncol. 2011. PMID: 20881474 Clinical Trial.
A phase I study of the pharmacokinetic and safety profiles of oral pazopanib with a high-fat or low-fat meal in patients with advanced solid tumors.
Heath EI, Chiorean EG, Sweeney CJ, Hodge JP, Lager JJ, Forman K, Malburg L, Arumugham T, Dar MM, Suttle AB, Gainer SD, LoRusso P. Heath EI, et al. Among authors: chiorean eg. Clin Pharmacol Ther. 2010 Dec;88(6):818-23. doi: 10.1038/clpt.2010.199. Epub 2010 Oct 27. Clin Pharmacol Ther. 2010. PMID: 20980999 Clinical Trial.
Phase I and pharmacokinetic study of CT-322 (BMS-844203), a targeted Adnectin inhibitor of VEGFR-2 based on a domain of human fibronectin.
Tolcher AW, Sweeney CJ, Papadopoulos K, Patnaik A, Chiorean EG, Mita AC, Sankhala K, Furfine E, Gokemeijer J, Iacono L, Eaton C, Silver BA, Mita M. Tolcher AW, et al. Among authors: chiorean eg. Clin Cancer Res. 2011 Jan 15;17(2):363-71. doi: 10.1158/1078-0432.CCR-10-1411. Epub 2011 Jan 11. Clin Cancer Res. 2011. PMID: 21224368 Clinical Trial.
Phase 1 study of the safety, tolerability, and pharmacokinetics of TH-302, a hypoxia-activated prodrug, in patients with advanced solid malignancies.
Weiss GJ, Infante JR, Chiorean EG, Borad MJ, Bendell JC, Molina JR, Tibes R, Ramanathan RK, Lewandowski K, Jones SF, Lacouture ME, Langmuir VK, Lee H, Kroll S, Burris HA 3rd. Weiss GJ, et al. Among authors: chiorean eg. Clin Cancer Res. 2011 May 1;17(9):2997-3004. doi: 10.1158/1078-0432.CCR-10-3425. Epub 2011 Mar 17. Clin Cancer Res. 2011. PMID: 21415214 Clinical Trial.
PR-104 plus sorafenib in patients with advanced hepatocellular carcinoma.
Abou-Alfa GK, Chan SL, Lin CC, Chiorean EG, Holcombe RF, Mulcahy MF, Carter WD, Patel K, Wilson WR, Melink TJ, Gutheil JC, Tsao CJ. Abou-Alfa GK, et al. Among authors: chiorean eg. Cancer Chemother Pharmacol. 2011 Aug;68(2):539-45. doi: 10.1007/s00280-011-1671-3. Epub 2011 May 19. Cancer Chemother Pharmacol. 2011. PMID: 21594722 Clinical Trial.
115 results